University of Monastir
um.rnu.tnTotal trials
109
Active
16
Phase 3
27
Total enrollment
77,965
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Magnesium Sulfate | — | — | — | — | 3 | ||
| atherolive | — | — | — | — | — | 2 | |
| Hypertonic sodium chloride 10% | — | — | — | — | — | 1 | |
| Sodium Chloride 0.9% | — | — | — | — | — | 1 | |
| Furosemide intravenous solution | — | — | — | — | — | 1 | |
| Gelafundin | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| atherolive-drug | — | — | — | — | — | 1 | |
| Terbutaline 2.5 mg | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | — | 1 | |
| Atherolive 500mg/day | — | — | — | — | — | 1 | |
| Atherolive 1000/day | — | — | — | — | — | 1 | |
| Placbo_Atherolive | — | — | — | — | — | 1 | |
| Piroxicam | — | — | — | — | 2 | ||
| paracétamol tramadol | — | — | — | — | — | 1 | |
| Paracétamol cafeine | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | — | — | — | 1 | |
| Mini bolus 50 | — | — | — | — | — | 1 | |
| Genetic polymorphism | — | — | — | — | — | 1 |
Next readouts
- 2024-08-22
- 2024-11-22
- 2024-12-15
- 2025-03-15
- 2025-08-30
- 2025-09-15
- 2025-12-01
- 2025-12-30
- 2027-06
- 2027-11-30
Top conditions
- Renal Colic10
- Acute Heart Failure8
- COPD Exacerbation5
- Acute Pain5
- Acute Coronary Syndrome5
- Dyspnea; Cardiac3
- Dyspnea3
- Heart Failure3
Frequently asked questions about University of Monastir
- How many clinical trials does University of Monastir have on ClinicalTrials.gov?
- University of Monastir is listed as the lead sponsor on 109 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Monastir's trials are in Phase 3?
- 27 of University of Monastir's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does University of Monastir focus on?
- University of Monastir's most-studied conditions on ClinicalTrials.gov are Renal Colic, Acute Heart Failure, COPD Exacerbation, Acute Pain, Acute Coronary Syndrome.
- When are University of Monastir's next clinical trial readouts?
- University of Monastir has 10 upcoming primary-completion readouts tracked here; the soonest is “Mini Bolus for Fluid Challenge Responsiveness in the Emergency Department”, expected around 2024-08-22.